Investigation of the miRNA146a and miRNA155 gene expression levels in patients with multiple sclerosis

Basit Öğe Kaydı
dc.contributor.authorShademan, Behrouz
dc.contributor.authorNourazarian, Alireza
dc.contributor.authorNikanfar, Masoud
dc.contributor.authorAvci, Cigir Biray
dc.contributor.authorHasanpour, Mehdi
dc.contributor.authorIsazadeh, Alireza
dc.date.accessioned2020-12-01T11:58:46Z
dc.date.available2020-12-01T11:58:46Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractMultiple sclerosis (MS) is a chronic inflammatory disease and the most common neurodegenerative status. MicroRNAs play an important role in macrophage response to inflammatory processes, and alterations in miRNA levels trigger the inactivation of specific T lymphocytes. As a result, these factors can lead to autoimmune diseases such as MS. Therefore, to determine the role of MicroRNA-146a and MicroRNA-155 in MS patients, their expression levels in serum of MS patients were compared with healthy controls. in this study, the expression levels of MicroRNA-146a and MicroRNA-155 in 30 serum samples of MS and healthy patients as a control group. MicroRNA extraction and cDNA synthesis was performed according manufacture protocols. the expression levels of MicroRNAs were evaluated by Real Time-PCR. MicroRNA-146a and MicroRNA-155 levels were increased in patients with MS compared to controls. the results demonstrated that EDSS score are increased with increasing level of MicroRNA-146a and MicroRNA-155. ROC curve analysis showed that the area under curve (AUC) was significant for MicroRNA-146a and MicroRNA-155. Increased expression levels of MicroRNA-146a and MicroRNA-155 may be associated with the pathogenesis of MS disease. If this study is conducted in a larger sample population and the above results can be used to identify patients or control patients who are under medical care. (C) 2020 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.jocn.2020.04.071en_US
dc.identifier.endpage193en_US
dc.identifier.issn0967-5868
dc.identifier.issn1532-2653
dc.identifier.pmid32331943en_US
dc.identifier.scopus2-s2.0-85083498543en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage189en_US
dc.identifier.urihttps://doi.org/10.1016/j.jocn.2020.04.071
dc.identifier.urihttps://hdl.handle.net/11454/62103
dc.identifier.volume78en_US
dc.identifier.wosWOS:000556833000031en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofJournal of Clinical Neuroscienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple Sclerosis (MS)en_US
dc.subjectMicroRNA-146aen_US
dc.subjectMicroRNA-155en_US
dc.subjectNovel inflammatory biomarkersen_US
dc.titleInvestigation of the miRNA146a and miRNA155 gene expression levels in patients with multiple sclerosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu